Scope
This guide provides a comprehensive clinical overview of BPC-157 within the Peptide Protocol Portal ecosystem and includes evidence-informed, physician-oriented frameworks for:
- Oral use via Peptide Protocol Portal RECOVER™ multi-phase enteric capsules — Staged-release BPC-157 delivery for systemic regenerative, gastrointestinal, and musculoskeletal support.
- Topical use as a stand-alone regenerative modality — Applications for dermal repair, inflammation reduction, and adjunctive aesthetic outcomes.
- Topical use in microneedling, RF microneedling, and laser-based procedures — Guidance for pre-conditioning, peri-procedural, and post-procedure regenerative support.
- Integration with PRiVIVE™ autologous platelet-derived serum — Dual-pathway collagen, angiogenesis, and anti-inflammatory synergy for advanced aesthetic and regenerative care.
- High-level considerations for reconstitution and injectable use of Peptide Protocol Portal BPC-157 10 mg lyophilized vials (research-use/off-label context only) — Including reconstitution options, peri-tendinous/peri-ligamentous protocols, mesotherapy grids, and systemic microdosing frameworks.
- Clinical decision trees, route-selection flowcharts, and protocol-building algorithms — To guide clinicians in selecting oral, topical, procedural, or injectable approaches based on patient phenotype, anatomical region, and therapeutic goals.
1. Clinical Overview of BPC-157
Molecule: Body Protection Compound-157 (Pentadecapeptide)
Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Class: Cytoprotective gastric pentadecapeptide; angiogenic, anti-inflammatory, musculoskeletal-restorative peptide.
Endogenous Context: Originally isolated from human gastric juice. In vivo, BPC-157 participates in:
- GI mucosal protection
- Endothelial and microvascular repair
- Regulation of nitric-oxide pathways
- Tendon/ligament fibroblast activation
- Systemic healing responses under physiologic stress
Physiological Observations in Literature
- Accelerated wound/tendon/ligament repair
- Rapid angiogenesis with organized vessel formation
- GI mucosal healing (upper & lower tract)
- Neuroprotection and microvascular stability
- Counteraction of NSAID-, steroid-, and alcohol-induced injury
- Stabilization of nitric-oxide (NO) and eNOS pathways
- Protection against endothelial dysfunction
- Organ-protective effects in models of ischemia/reperfusion
2. Mechanisms of Action
BPC-157's activity is multi-pathway, involving cytoprotective, microvascular, and fibroblastic signaling systems.
A. Angiogenesis & Microvascular Repair
- Rapid induction of stable, non-leaky vessel formation
- Stimulation of VEGF receptor signaling without excessive VEGF release
- Upregulates early-phase angiogenic markers
- Supports endothelial cell survival and migration
B. Fibroblast Activation & Collagen Synthesis
- Increases fibroblast proliferation in tendon/ligament tissue
- Enhances collagen type I organization
- Accelerates the tendon-to-bone and ligament-to-bone healing interface
- Improves tensile strength in healing tissues
C. GI Mucosal Healing
- Restores tight-junction integrity
- Protects against NSAID-induced gastric damage
- Normalizes motility disturbances
- Supports lower-GI mucosa (colitis models)
D. Neuroprotective & Neuromodulatory Actions
- Reduces oxidative stress in the CNS
- Stabilizes neuronal microcirculation
- Modulates dopaminergic systems
- Protective effects in models of traumatic brain injury
E. Endothelial Protection
- Counteracts endothelial dysfunction triggered by endotoxin, alcohol, NSAIDs
- Improves NO (nitric oxide) microregulation
- Increases eNOS coupling
F. Anti-Inflammatory Modulation
- Downregulates TNF-α, IL-6, and inflammatory cascades
- Reduces edema and inflammatory infiltration in injured tissues
- Decreases oxidative and nitrosative stress markers
3. Evidence Summary — Clinical Domains of Interest
3.1 GI & Mucosal Integrity
Demonstrated actions:
- Accelerates ulcer healing (NSAID, stress, alcohol-induced models)
- Restores tight-junction function
- Reduces inflammatory infiltrates in colitis models
- Protects against esophageal, stomach, and intestinal mucosal damage
3.2 Musculoskeletal & Orthopedic Healing
Convergent findings:
- Enhances fibroblast recruitment
- Faster tendon healing post-transection
- Increased tensile strength of repaired tissue
- Enhanced collagen organization
- Improved recovery after muscle crush injury
- Promotes healing of medial collateral ligament injuries
3.3 Endothelial & Microvascular Protection
Documented findings:
- Stabilizes vascular endothelium
- Accelerates angiogenesis without dysfunctional vessel formation
- Counteracts endothelial injury from endotoxin, NSAID, and alcohol models
- Improves peripheral circulation
- Reduces edema and tissue ischemia
3.4 Neurological Protection
- Reduced brain swelling and edema in TBI models
- Support for dopaminergic balance
- Protection against neurotoxic insults
- Improved nerve regeneration in peripheral injury
3.5 Systemic Anti-Inflammatory Effects
- Downregulates TNF-α, IL-1β, IL-6
- Reduces oxidative burden
- Protects organs under systemic inflammatory stress
- Supports mitochondrial resilience in injury states
4. Oral BPC-157 Protocol — Peptide Protocol Portal RECOVER™
4.1 Formulation Summary — RECOVER™ Capsule
- BPC-157 — 500 mcg
- GHK-Cu — 2 mg
- Carnosine — 500 mg
Multi-Phase Enteric Delivery System
- Enteric-coated capsule — pH-triggered dissolution ≥5.5 (duodenum/jejunum)
- Immediate-release micro-pellets: Carnosine → antioxidant, anti-glycation, supports mucosal health
- Sustained-release pellet matrix: GHK-Cu → collagen signaling, matrix remodeling
- Delayed-release micro-pellets: BPC-157 → GI regenerative, endothelial protective, musculoskeletal restorative
Purpose: Staged, sequential activation of healing pathways → antioxidant → ECM remodeling → angiogenesis + tissue repair.
4.2 Oral Clinical Protocol
- Dose: 1 capsule every morning on an empty stomach
- Cycle: 5 days on / 2 days off
- Course length: 60-capsule bottle ≈ 3 months (at 5/2 cycling)
- Take with 8–12 oz water
- Avoid coffee/acidic beverages for ~30 minutes
- Compatible with fasting protocols
- May be combined with PRP, Shockwave (ESWT), needling, or orthopedic therapies
4.3 Clinical Use Cases (Oral)
A. GI & Mucosal Support
Patients with gastritis, dyspepsia, NSAID history, or mucosal irritation.
B. Orthopedic Recovery
Adjunct for acute injuries, chronic tendinopathy, ligament sprains.
C. Athletic Recovery
Useful in high-output training cycles, inflammation bursts, or overuse patterns.
D. Post-Procedure Adjunct
Pairs with PRP, microneedling, joint injections, shockwave, RF/laser.
E. Systemic Regenerative Protocols
When combined with RECOVER™, REVIVE™, or REBALANCE™ depending on phenotype.
4.4 Decision Tree 1 — Should You Use Oral RECOVER™?
Is there a musculoskeletal or GI-related condition present?
→ Yes: Consider as first-line systemic support
→ No: Continue to next question
Is the patient undergoing procedures that stress tissue or require repair?
(Ortho injections, PRP, microneedling, RF/laser, surgery)
→ Yes: Oral RECOVER™ recommended
→ No: Proceed to next
Does the patient experience chronic inflammation, slow recovery, or endothelial dysfunction symptoms?
→ Yes: Oral RECOVER™ recommended
→ No: Optional adjunct based on goals
Any contraindications? Pregnancy/lactation (avoid), Active cancer (case-by-case), Severe hepatic disease, Known hypersensitivity
→ If any present: Avoid or use with close monitoring
4.5 Monitoring During Oral Protocol
Subjective:
- Pain reduction
- Mobility gains
- GI comfort changes
- Reduced recovery time
Objective (as needed):
- Inflammatory markers
- Doppler/ultrasound in orthopedic cases
- GI symptom inventory
- Liver panel in high-risk patients
5. Injectable BPC-157 Protocols
(Off-label / research context — educational guidance only)
Peptide Protocol Portal provides a 10 mg lyophilized BPC-157 vial for clinicians trained in peptide-based regenerative strategies. All injections must follow sterile technique, state scope-of-practice rules, and documented informed consent.
5.1 Product Summary
Strength: 10 mg BPC-157
Diluent: Bacteriostatic saline (0.9%)
Storage: Store vials refrigerated (2–8°C). After reconstitution: 7–14 days refrigerated is common.
5.2 Reconstitution Options (Clinician-Selectable)
Reconstitute 10 mg vial with 2 mL bacteriostatic saline
1 mL = 5 mg · 0.1 mL = 0.5 mg (500 mcg)
Use case: Localized tendon/ligament injections, peri-lesional microdosing
Reconstitute 10 mg vial with 5 mL bacteriostatic saline
1 mL = 2 mg · 0.1 mL = 0.2 mg (200 mcg)
Use case: Field injections, mesotherapy patterns, moderate lesion spread
Reconstitute 10 mg vial with 10 mL bacteriostatic saline
1 mL = 1 mg · 0.1 mL = 0.1 mg (100 mcg)
Use case: Large-area mesotherapy, peritendinous grids, dermal applications
5.3 General Injectable Protocol Guidance
Route Options (Educational Context)
- Subcutaneous (systemic or regional effects)
- Peri-tendinous / periligamentous
- Intra-dermal (mesotherapy style)
- Peri-lesional microinjection
Peptide Protocol Portal does not recommend or endorse intra-articular injection of BPC-157.
- 250–500 mcg per injection site, 1–3× weekly
- Larger lesions: up to 1 mg per site, based on clinical judgment
- Duration: 2–6 weeks, then reassess
Injection Technique Principles
- Always aspirate for negative blood return
- Use fine-gauge needles (30–32g for mesotherapy; 27–30g for peritendinous)
- Avoid injecting into tendons directly; stay peri-tendinous
- Rotate injection sites
5.4 Example Injection Strategy Templates
A. Peri-Tendinous Protocol (e.g., Achilles, patellar, elbow tendinopathy)
- Volume per site: 0.1–0.3 mL
- Number of sites: 3–6 around lesion
- Total per session: 0.5–2 mg
- Frequency: 1× weekly × 3–6 weeks
B. Peri-Ligamentous Protocol (e.g., MCL, LCL, ATFL)
- Volume per site: 0.1–0.2 mL
- Pattern: Fan or linear pattern along fibers
- Frequency: 1× every 5–7 days × 3–4 weeks
C. Mesotherapy Pattern (Dermal / scar / large-field tissue)
- Concentration: 1 mg/mL preferred
- Injection depth: 1–3 mm
- Spacing: 1 cm grid
- Frequency: weekly × 4–6 sessions
D. Subcutaneous Microdosing (Systemic Support)
- Dose: 250–500 mcg
- Frequency: daily–3× weekly
- Used for: systemic inflammation, gut recovery, broad tissue stress
5.5 Decision Tree 2 — Should Injectable BPC-157 Be Used?
Has the patient failed topical/oral/systemic protocols?
→ No: Try conservative approaches first
→ Yes: Continue
Is the pathology localized and structural?
(Tendon, ligament, scar, localized chronic inflammation)
→ Yes: Injectable route may be appropriate
→ No: Oral/systemic routes may be better
Does the clinician have training in peri-tendinous/peri-ligamentous injection?
→ No: Avoid or refer
→ Yes: Proceed
Any contraindications? Active infection, Coagulation disorders, Active cancer, Poor wound healing disorder
→ If yes: Avoid or modify plan
6. Topical & Procedural Use Protocols
6.1 Topical Use (Adjunct)
Indications:
- Soft-tissue injury
- Local dermal recovery
- Post-procedural inflammation reduction
Vehicle: Hydrogel, serum, hyaluronic acid base
Frequency: Once or twice daily to target area
Note: Topical BPC-157 is less studied than oral or injectable forms; use as supportive adjunct only.
6.2 Procedural Integration
A. Orthopedic Procedures
- Combine with PRP, shockwave, or laser therapies
- Oral RECOVER™ during PRP series to potentially enhance outcomes
- Injectable BPC-157 can be used at alternating intervals
B. Aesthetic Procedures
- Post-RF, post-laser, or post-needling to reduce inflammation
- Consider using after barrier integrity returns
C. GI/Functional Medicine Settings
- Oral RECOVER™ as part of SIBO, gastritis, or inflammatory gut repair protocols
- Avoid topical/IV use in GI indications
7. Clinical Decision Trees & Flowcharts
Decision Tree 3 — Route Selection (Oral vs. Injectable vs. Topical)
Step 1 — Is the issue systemic or localized?
Systemic inflammation / gut issues → Oral RECOVER™
Localized structural injury → Injectable
Dermal/aesthetic recovery → Topical ± oral
Step 2 — Severity of pathology
Mild → Oral ± topical
Moderate → Oral + targeted injections
Severe → Multi-route approach (oral + injections + procedural)
Step 3 — Timeline
Immediate recovery needed → Injectable
Long-term remodeling → Oral
Step 4 — Contraindications
Pregnancy/lactation → Avoid · Cancer → Case-by-case · Severe liver disease → Avoid or monitor · Bleeding disorder → Avoid injection route
Flowchart — BPC-157 Musculoskeletal Protocol Builder
|-- No → Oral RECOVER™ optional for systemic support
|-- Yes → Identify tissue type:
|-- Tendon → Tendon Protocol
|-- Ligament → Ligament Protocol
|-- Muscle → consider mesotherapy or SC microdosing
Tendon Protocol:
Pain < 3 months? Acute → oral + 1–3 injections
Pain > 3 months? Chronic → oral + 3–6 injections + therapy
Ligament Protocol:
Grade 1 → oral RECOVER™ + supportive bracing
Grade 2 → oral + peri-ligamentous injections weekly × 4
Grade 3 → refer for surgical evaluation; may use oral support
Muscle Protocol:
Small tear → oral + topical
Large tear → oral + mesotherapy + PRP
8. Safety, Contraindications & Monitoring
8.1 Safety Overview
BPC-157 demonstrates a broad safety margin in preclinical literature; however, clinical use is investigational, experimental, and off-label.
8.2 Contraindications
Absolute:
- Pregnancy
- Lactation
- Known hypersensitivity
Relative:
- Active malignancy
- Severe hepatic disease
- Coagulation disorders (injectables)
- Active infection at injection site
- Pediatric use (insufficient data)
8.3 Monitoring Parameters
Subjective:
- Pain scores
- Functional improvement
- GI symptom changes
- Recovery time after exercise or procedures
Objective:
- Ultrasound for tendon/ligament pathology
- Inflammation markers (CRP, ESR)
- Liver function (if high-dose use or comorbid conditions)
- Neurocognitive assessment post-concussion
9. Integrated Treatment Archetypes
Archetype A — Orthopedic / Tendonopathy Protocol
Systemic Backbone:
- RECOVER™: 1 cap AM, 5-on/2-off × 12 weeks
Local Therapy:
- Peri-tendinous BPC-157 injections weekly × 4–6
- Optional: topical BPC-157 gel on off-days
Adjuncts: Physical therapy, PRP (optional)
Archetype B — GI Support / Mucosal Recovery
Systemic:
- RECOVER™ daily as above
- REBALANCE™ PM for autonomic/nervous system support (optional)
Adjuncts: Low-acid diet, discontinue NSAIDs if possible, add probiotic or mucosal support agents as clinically indicated
Archetype C — Athletic Recovery / High-Output Performance
Systemic:
- RECOVER™ AM
- REVIVE™ AM for mitochondrial support
Local:
- SC microdosing 250–500 mcg q48h
- Topical BPC-157 as needed
Adjunct: Compression therapy, electrolyte optimization
Archetype D — Neurovascular / Neuroinflammatory Support
Systemic:
- RECOVER™ AM
- REBALANCE™ PM (neurological adjunct)
Adjunct: Omega-3 support, sleep optimization, avoid neurotoxicants
Legal Disclaimer
The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.
BPC-157, SLU-PP-332, 5-Amino-1MQ, and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.
Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.
Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.
By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.
Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.